sorafenib has been researched along with Disease Models, Animal in 171 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (5.85) | 29.6817 |
| 2010's | 133 (77.78) | 24.3611 |
| 2020's | 28 (16.37) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, YI; Chao, YS; Chen, CP; Chen, CT; Chen, CW; Cheng, AH; Chou, LH; Hsieh, SY; Hsu, JT; Hsu, T; Huang, YL; Jiaang, WT; Lin, WH; Lu, CT; Tseng, YJ; Yeh, TK; Yen, KR; Yen, SC | 1 |
| Jiao, Y; Lu, X; Tang, W; Wu, J; Xin, BT; Zhang, Y; Zheng, Y; Zhou, X | 1 |
| Cao, YX; He, YY; Mao, S; Xiao, X; Xie, XX; Xin, MH; Xuan, W; Zhang, S; Zhang, SQ; Zuo, SJ | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Chao, CH; Chen, LH; Chen, Y; Chen, YT; Cheng, HT; Huang, HC; Huang, KH; Huang, KW; Jin, PR; Juang, IP; Lee, TY; Liao, YH; Lin, SL; Lin, TC; Liu, ZY; Sheng, YH; Su, CT; Sung, YC; Wang, HC; Wang, J | 1 |
| Azadbakht, A; Gharibzadeh, S; Hajighasemlou, S; Mirmoghtadaei, M; Muhammadnejad, S; Nikbakht, M; Pakzad, S; Seyhoun, I; Verdi, J | 1 |
| Bae, KH; Chan, KH; Chen, Q; Her, Z; Kurisawa, M; Lai, F; Mong, J; Niibori-Nambu, A; Osato, M; Tan, MH | 1 |
| Fang, Z; Li, Y; Lu, Y; Wang, H; Wang, M; Wu, Y; Xu, X | 1 |
| Kim, SK; Park, JS; Park, S; Park, SJ | 1 |
| Chang, HJ; Chang, HS; Kim, Y; Lee, SY; Park, KC; Yun, HJ | 1 |
| Feng, L; Jiang, X; Jin, H; Lu, K; Wang, W; Wang, X; Wei, Q; Zhu, L | 1 |
| Choi, KH; Kim, CW; Kim, SM; Kim, Y; Lee, JH; Park, KC; Weicker, R; Yun, HJ | 1 |
| Dong, H; Jing, W; Jun, X; Min, M; Runpeng, Z; Shuo, L; Yingru, X | 1 |
| Belt, P; Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Kline, Z; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N | 1 |
| Chen, J; Jia, H; Lin, J; Lin, Z; Lu, L; Lu, M; Luo, M; Qin, L; Shao, W; Zhu, W | 1 |
| Chang, TS; Chi, CC; Huang, YH; Kuo, YC; Lai, SC; Lan, PC; Lee, KF; Su, YT; Wu, YC; Yang, MH | 1 |
| Chu, Y; He, C; Hua, QM; Li, JZ; Liao, J; Mao, K; Wen, WP; Wu, Y; Xiao, Z; Zeng, DN; Zheng, L; Zhu, LY | 1 |
| Cheng, Q; Hu, S; Li, Z; Wang, S; Wang, Y; Xiang, X; Xun, X; Zhang, C; Zhu, J | 1 |
| Chen, CT; Chow, LP; Huang, YH; Liao, LZ; Lin, JH; Lin, YK; Lu, CH | 1 |
| Cao, J; Chen, X; Du, J; He, Q; Luo, P; Ma, S; Xu, Z; Yan, H; Yang, B; Zeng, S; Zhang, X; Zhang, Y; Zhao, Z; Zhu, Y | 1 |
| Bresnahan, E; Lindblad, KE; Lujambio, A; Ruiz de Galarreta, M | 1 |
| Chen, Y; Huang, M; Huang, Q; Sun, C; Sun, R; Tian, Z; Wang, J; Wei, H; Wu, Y; Xiao, W; Zheng, X | 1 |
| Aydemir, O; Balbaba, M; İlhan, N; Özercan, İH; Yildirim, H | 1 |
| Manoharan, R; Natarajan, SR; Ponnusamy, L; Thangaraj, K | 1 |
| Liu, Y; Lv, P; Ma, L; Man, S; Yang, L; Yao, J | 1 |
| Armeli Iapichino, EC; Bramanti, A; Bramanti, P; Ciurleo, R; Fagone, P; Magro, GG; Mangano, K; Nicoletti, F; Pesce, A; Petralia, MC | 1 |
| Chang, Y; Cho, EJ; Kim, YJ; Lee, JH; Lee, YB; Yoon, JH; Yu, SJ | 1 |
| Bonney, G; Chow, P; Dan, YY; Huang, DQ; Jumat, H; Kow, A; Lee, GH; Lim, SG; Lim, YT; Muthiah, MD; Pang, YH; Shridhar, I; Soon, G; Tan, WX; Wee, A; Zhou, L | 1 |
| Han, JK; Kim, JH; Lee, S; Ryu, H | 1 |
| Chen, P; Chung, RT; Dai, G; He, L; Hong, J; Hu, K; Jiang, Y; Li, J; Lin, W; Peng, S; Qu, C; Tu, M; Xie, P; Yuan, H; Zheng, D | 1 |
| Bi, L; Chen, F; Chen, W; Du, L; Feng, M; Jiang, Y; Jiao, Q; Meng, P; Ren, Y; Tang, B; Wang, C; Wang, Q; Wang, Y; Zhou, F | 1 |
| Abbate, I; Apicella, I; Bucolo, C; D'Agata, V; De Falco, S; Giuliano, F; La Rosa, LR; Maugeri, G; Mazzone, MG; Platania, CBM; Santonocito, M; Solfato, E; Tarallo, V; Viola, S; Zappulla, C | 1 |
| Borgmann, M; Hamm, S; Hermann, F; Kallus, H; Parnitzke, U; Schrepfer, S; Streubel, G; Wulff, T | 1 |
| Hoe, HS; Kim, J; Park, JH; Park, SK | 1 |
| Choe, SW; Kim, MJ; Kim, YH; Lee, YJ; P Oh, S; Sprecher, D | 1 |
| Cho, HJ; Cho, HR; Choi, JW; Chung, JW; Kim, DD; Kim, HC; Park, JH | 1 |
| Chen, CP; Liao, XH; Liu, H; Lu, KP; Lu, W; Wang, J; Wang, L; Xu, H; Yang, D; Zhang, AL; Zheng, M; Zhou, XZ | 1 |
| DeVere White, RW; Duan, Z; Ho, PY; Jian, C; Lam, KS; Lara, PN; Qiu, JX; Tu, MJ; Wun, T; Yu, AM; Yu, AX; Zhang, Q | 1 |
| Cho, EJ; Cho, H; Cho, KH; Cho, SH; Choi, WM; Hwang, CY; Jang, JJ; Kim, CY; Kim, K; Kim, YJ; Lee, JH; Lee, KB; Park, SM; Suh, KS; Won, JK; Yoon, JH; Yu, SJ | 1 |
| Chen, DS; Chen, KF; Chen, LJ; Chen, PJ; Hu, TC; Huang, KW; Huang, YJ; Jao, P; Kao, JH; Liu, CH; Liu, CJ; Shiau, CW; Su, TH; Tai, WT; Tseng, TC; Wu, YM; Yang, HC; Yang, NJ | 1 |
| Murata, K; Nitta, N; Nitta-Seko, A; Ohta, S; Sonoda, A; Tomozawa, Y; Tsuchiya, K; Watanabe, S | 1 |
| Augustyns, K; Bräsen, JH; Feldmann, F; Fulda, S; Goossens, V; Hofmans, S; Jeong, M; Joossens, J; Lee, EW; Linkermann, A; Martens, S; Song, J; Takahashi, N; Tonnus, W; Van der Veken, P; Vandenabeele, P | 1 |
| Fang, C; Gao, P; Geng, P; Guo, L; Hu, C; Li, E; Liu, Y; Sun, M; Tang, L; Wang, C; Wang, J; Wang, Y; Xu, G; Yin, P; Yu, J; Zeng, J; Zhuang, Z | 1 |
| Koraka, P; Kycko, A; Marzec, A; Orłowska, A; Osterhaus, A; Reichert, M; Smreczak, M; Trębas, P; Żmudziński, JF | 1 |
| Baldassarre, M; Bolondi, L; Fornari, F; Giannone, FA; Giovannini, C; Gramantieri, L; Marinelli, S; Negrini, M; Patrizi, C; Pollutri, D; Porretti, L; Quarta, S; Trombetta, E; Van Vlierberghe, H; Vandewynckel, YP; Vandierendonck, A | 1 |
| Cagan, RL; Dar, AC; Maldonado, AY; Murray, MA; Real, A; Schlessinger, A; Scopton, AP; Silber, L; Sonoshita, M; Ung, PMU | 1 |
| Cheng, Y; Wang, B; Xu, J; Xu, W; Zheng, H; Zhu, Y | 1 |
| Chi, H; Meng, Z; Wang, H; Zhang, C | 1 |
| Barbier, EL; Coquery, N; Lemasson, B; Rémy, C; Serduc, R | 1 |
| Hikasa, Y; Leong, ZP | 1 |
| Booth, L; Dent, P; Poklepovic, A; Roberts, JL | 1 |
| Ding, WQ; Hannafon, B; Jiao, Y; Watts, T; Xue, J | 1 |
| Avritscher, R; Bankson, JA; Cortes, AC; Ensor, JE; Kingsley, CV; Maldonado, KL; Minhaj, AA; Mitchell, JM; Muñoz, NM; Polak, U; Rashid, A; Taghavi, H | 1 |
| Cao, J; Chen, X; Chen, Y; Li, W; Luo, X; Shang, C; Tan, W; Zhong, J; Zhou, R; Zhu, S | 1 |
| Cai, J; Gao, Q; Han, Y; Hezam, K; Jiang, J; Liu, Y; Sun, F; Wang, M; Wang, T; Xie, J; Zhang, J; Zhang, X | 1 |
| Arai, S; Fukuda, K; Hirata, E; Matsui, J; Nishiyama, A; Ohtsubo, K; Onoda, N; Taira, S; Takeuchi, S; Taniguchi, H; Tanimoto, A; Wang, R; Yamada, T; Yamashita, K; Yano, S | 1 |
| Al-Abdulla, R; Alonso-Peña, M; Andersen, JB; Asensio, M; Avila, MA; Banales, JM; Briz, O; Del Carmen, S; Lozano, E; Macias, RIR; Marin, JJG; Martinez-Chantar, ML; Monte, MJ; Munoz-Garrido, P; O'Rourke, CJ; Sanchez-Vicente, L; Satriano, L | 1 |
| Bissinger, S; Hage, C; Hoves, S; Kiessling, F; Pöschinger, T; Prinz, Y; Ries, CH; Strauss, L | 1 |
| Di, S; Jiang, H; Li, H; Li, Z; Liu, Y; Luo, H; Shi, B; Su, J; Sun, R; Wu, X | 1 |
| Du, Y; Kong, L; Liang, Q; Tian, J; Zhu, X | 1 |
| Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N | 1 |
| Dai, Z; Fan, J; Gu, F; Huang, X; Jiang, J; Tan, C; Wang, Z; Xu, M; Yan, J; Zhou, J | 1 |
| Bu, Y; Chai, ZT; Jia, QA; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, M; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhu, XD | 1 |
| Ding, ZB; Fan, J; Gu, CY; Hui, B; Liu, WR; Peng, YF; Qiu, SJ; Shi, YH; Yang, H; Zhou, J | 1 |
| Waxman, DJ; Zhang, K | 1 |
| Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD | 1 |
| Chan, C; Felsher, DW; Gamrekelashvili, J; Greten, TF; Hewitt, S; Kapanadze, T; Kapoor, V; Korangy, F; Ma, C; Manns, MP; Zender, L; Zhao, F | 1 |
| Andersen, NJ; Baker, LH; Boguslawski, EA; Dawes, MJ; Duesbery, NS; Dykema, KJ; Froman, RE; Furge, KA; Kamstock, DA; Kitchell, BE; Krivochenitser, RI; Nickoloff, BJ; Thomas, DG | 1 |
| Baron Toaldo, M; Bolondi, L; Cipone, M; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L | 1 |
| Chen, L; Qin, J; Wang, GL; Wei, YZ; Xu, YY; Zhang, YX; Zhou, JM; Zhu, YY | 1 |
| Alpini, G; Fallon, MB; Hu, B; Venter, J; Wu, W; Yang, W; Zhang, J | 1 |
| Liu, YL; Wang, JL; Wang, ZH; Xi, Y; Zhang, Q | 1 |
| Chen, Y; Duda, DG; Duyverman, AM; Hiddingh, L; Huang, P; Huang, Y; Jain, RK; Koppel, C; Lauwers, GY; Reiberger, T; Roberge, S; Samuel, R; Zhu, AX | 1 |
| Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H | 1 |
| Chen, CH; Chen, CS; Chen, MC; Liou, JP; Pan, SL; Teng, CM; Tsai, AC; Wang, JC | 1 |
| Inoue, K; Kamada, M; Karashima, T; Kawada, C; Komatsu, T; Kuroda, N; Niimura, M; Shuin, T; Udaka, K | 1 |
| Croft, SL; Sanderson, L; Yardley, V | 1 |
| Ambrosetti, D; Amiel, J; Gastaud, L; Grépin, R; Marsaud, A; Pagès, G; Pedeutour, F | 1 |
| Chen, C; Daily, MF; Galuppo, R; Gedaly, R; Maynard, E; Shah, M; Spear, BT | 1 |
| Barbe, M; Berretta, RM; Dunn, J; Duran, JM; Force, T; Gao, E; Gross, P; Houser, SR; Husain, S; Kubo, H; Lal, H; Makarewich, CA; Sharp, TE; Starosta, T; Trappanese, D; Vagnozzi, RJ; Yu, D | 1 |
| Chen, D; Chen, M; Kuang, M; Lencioni, R; Peng, B; Peng, H; Peng, S; Shen, S; Wang, Y | 1 |
| Bogdanova, A; Daryadel, A; Frossard, N; Gassmann, M; Lehalle, C; Mueller, X; Seifert, B; Tavakoli, R; Zünd, G | 1 |
| Baron Toaldo, M; Bolondi, L; Croci, L; Diana, A; Marinelli, S; Milazzo, M; Palamà, C; Pecorelli, A; Piscaglia, F; Salvatore, V; Venerandi, L | 1 |
| Arnold, B; Augustin, HG; Bergeest, JP; Géraud, C; Goerdt, S; Hu, J; Komljenovic, D; Mogler, C; Neumann, A; Rohr, K; Runge, A; Schirmacher, P; Wieland, M | 1 |
| Cho, NP; Cho, SD; Hong, IS; Jung, JY; Nam, JS; Shin, JA; Yu, HJ | 1 |
| Chen, IT; Chen, KF; Hsu, CY; Li, YS; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH; Wu, SH | 1 |
| Chang, CJ; Cheng, AL; Gandhi, AK; Hsu, C; Huang, ZM; Jeng, YM; Liao, SC; Lin, YJ; Lin, ZZ; Ou, DL | 1 |
| D'Argenio, DZ; Hsu, CP; Huard, J; Kuchimanchi, M; Lu, JF; Ma, J; Sun, YN; Weidner, M; Xu, G; Xu, Y; Zhang, Y | 1 |
| Chang, YF; Chuang, HY; Hwang, JJ; Liu, RS | 1 |
| Chen, G; Li, H; Wang, Z; Xu, X; You, W; Zhang, J; Zhou, D | 1 |
| Li, H; Liang, Q; Liu, B; Ma, Y; Mei, X; Wang, Y | 1 |
| Dill, MT; Djonov, V; Heim, MH; Hlushchuk, R; Makowska, Z; Quagliata, L; Rothweiler, S; Semela, D; Terracciano, L | 1 |
| Duan, F; Fan, QS; Fu, JX; Liu, FY; Wang, MQ; Zhang, L | 1 |
| Chen, Z; Duan, Z; Fu, R; Ge, H; Gui, B; Han, J; Jia, L; Ma, X; Ou, Y; Tian, L; Wang, L | 1 |
| Barbeiro, DF; Bida, PM; Carrilho, FJ; Coelho, AM; Cogliati, B; D'Albuquerque, LA; Kubrusly, MS; Mazo, DF; Oliveira, CP; Pereira, IV; Souza, HP; Stefano, JT; Torres, MM; Xerfan, MP | 1 |
| Cheng, BY; Ching, RH; Lau, EY; Lee, TK; Lo, J; Ma, MK; Ng, IO | 1 |
| De Velasco, MA; Hatanaka, Y; Kura, Y; Minami, T; Nishio, K; Nozawa, M; Oki, T; Ozeki, T; Shimizu, N; Uemura, H; Yamamoto, Y; Yoshikawa, K; Yoshimura, K | 1 |
| Akkar, OB; Cetin, A; Kacan, SB; Kacan, T; Karakus, S; Ozer, H; Yildiz, C | 1 |
| Altomonte, J; Braren, R; Dworniczak, J; Ebert, O; Esposito, I; Feuchtinger, A; Groß, C; Heid, I; Heß, J; Rummeny, E; Sayyed, S; Schlitter, AM; Schwaiger, M; Settles, M; Steiger, K; Steingötter, A; Unger, K; Walch, A; Zitzelsberger, H | 1 |
| Im, GH; Jeon, TY; Kim, CK; Kim, JH; Lee, JH; Park, BK | 1 |
| Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P | 1 |
| Heikenwalder, M; O'Connor, T; Weber, A | 1 |
| Di Cesare Mannelli, L; Farina, C; Ghelardini, C; Maresca, M; Scherz, MW | 1 |
| Choi, BI; Choi, WS; Han, JK; Kim, J; Kim, JH; Kim, YJ; Yoon, SH | 1 |
| Devapatla, B; Sharma, A; Woo, S | 1 |
| Chang, HC; Chen, CS; Chen, YW; Chiu, HC; Huang, YT; Shiau, CW; Su, JC; Teng, LJ | 1 |
| Chen, L; Ge, C; Li, H; Li, J; Li, M; Liu, J; Tian, H; Wang, T; Yao, M; Zhang, L; Zhao, F | 1 |
| Cheng, CW; Hsieh, YH; Lin, CL; Lin, MT; Lin, TY; Tsai, JP; Wu, CC; Yang, SF | 1 |
| Axelrod, JH; Divon, MS; Galun, E; Lanton, T; Peretz, T; Salmon, A; Sonnenblick, A; Zahavi, T | 1 |
| Cai, Y; Gao, D; Gao, L; Jia, B; Lai, J; Liu, H; Liu, Z; Wang, F; Zhang, C | 1 |
| Cai, X; Chang, C; Jin, RA; Li, G; Lin, H; Ma, WL; Shi, L; Sun, Y; Xu, J; Yeh, S | 1 |
| Bar-Zion, A; Butz, H; Daley, F; Foster, FS; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S; Reynolds, AR; Vermeulen, PB; Yin, M; Yousef, GM | 1 |
| Ahmed, AA; Elnakish, MT; Floyd, K; Janssen, PM; Mohler, PJ; Saad, NS | 1 |
| Abd El-Fattah, EE; El-Ashmawy, NE; El-Bahrawy, HA; Khedr, EG | 1 |
| Fujiwara, T; Kagawa, S; Katsube, R; Kimura, F; Matsukawa, A; Ninomiya, T; Noma, K; Nouso, K; Ohara, T; Shirakawa, Y; Tazawa, H; Tomono, Y; Urano, S; Yamamoto, K | 1 |
| Campana, D; Chang, YH; Kamiya, T | 1 |
| Fergusson, D; Henderson, VC; Kimmelman, J; MacKinnon, N; Mattina, J | 1 |
| Dolcet, X; Dosil, MA; Eritja, N; Felip, I; Gatius, S; Matias-Guiu, X; Mirantes, C; Santacana, M | 1 |
| Burgoyne, AM; Durden, DL; Garlich, JR; Ikeda, S; Joshi, S; Kono, Y; Morales, GA; Sicklick, JK; Singh, AR | 1 |
| Cai, X; Chang, C; Chen, J; Li, G; Lin, H; Shi, L; Sun, Y; Xu, J | 1 |
| Dong, X; Han, P; Jiang, H; Jiang, X; Qiao, H; Sun, X; Tan, G; Tang, S; Zhai, B | 1 |
| He, C; Li, Q; Liu, C; Liu, Q; Ma, W; Tao, L; Wang, X; Xue, D; Zhang, J; Zhang, W | 1 |
| Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B | 1 |
| Angenstein, F; Baldauf, L; Daniel, EA; Kirches, E; Mawrin, C; Pachow, D; Scholz, J; Stork, O; Tuchen, M; Wilisch-Neumann, A | 1 |
| Gallacher, D; Gallacher, J; Jones, A; Narov, K; Sampson, JR; Samsel, PA; Shen, MH; Yang, J | 1 |
| Aihara, A; Akiyama, Y; Arii, S; Ban, D; Kudo, A; Matsumura, S; Mitsunori, Y; Mogushi, K; Nakao, K; Ochiai, T; Ohata, Y; Shimada, S; Tanabe, M; Tanaka, S | 1 |
| Cheong, H; Hong, SM; Kim, N; Lee, CK; Lee, SS; Lee, Y; Son, WC | 1 |
| Chow, PK; Chung, A; Huynh, H; Lam, IW; Lee, JW; Lew, GB; Ngo, VC; Ong, HS; Soo, KC | 1 |
| Abe, K; Arimura, A; Hojo, K; Iguchi, M; Matsumoto, M; Matsuo, Y; Wada, T | 1 |
| Aburatani, H; Hirakawa, K; Iwata, C; Johansson, E; Kano, MR; Kiyono, K; Komuro, A; Matsumoto, Y; Miyazono, K; Miyoshi, H; Morishita, Y; Shirai, YT; Suzuki, HI; Watanabe, A; Yashiro, M | 1 |
| Dabora, SL; Lee, N; Messina, MP; Nobil, AM; Rauktys, AE; Woodrum, CL | 1 |
| English, BC; Figg, WD; Price, DK | 1 |
| Chong, LW; Chow, P; Chung, A; Huynh, H; Koong, HN; Lam, WL; Lee, J; Lee, SS; Lew, GB; Ngo, VC; Ong, HS; Ong, WJ; Soo, KC; Thng, CH; Yang, S | 1 |
| Choo, SP; Chow, P; Chung, A; Goh, BC; Huynh, H; Koong, HN; Ngo, VC; Ong, HS; Poon, D; Smith, PD; Soo, KC; Thng, CH; Toh, HC | 1 |
| Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC | 1 |
| Burgess, S; Echeverria, V | 1 |
| Hutson, T | 1 |
| Altieri, DC; Gilbert, CA; Raskett, CM; Ross, AH; Siegelin, MD | 1 |
| Barbier, EL; Bouchet, A; Coquery, N; Le Duc, G; Lemasson, B; Maisin, C; Rémy, C; Robert, P; Serduc, R; Troprès, I | 1 |
| Duffy, A; Greten, T | 1 |
| Cheng, SQ; Deng, YZ; Feng, YX; Guan, DX; Li, JJ; Li, N; Qin, Y; Wang, H; Wang, HY; Wang, T; Wang, XF; Wu, MC; Xie, D; Yang, P; Yao, F; Zhu, YQ | 1 |
| Lowe, SW; Pardee, TS; Zuber, J | 1 |
| Cripe, TP; Dombi, E; Jousma, E; Kim, A; Kim, MO; Lindquist, D; Ratner, N; Schnell, BM; Scott Dunn, R; Widemann, BC; Wu, J | 1 |
| Abe, K; Alzoubi, A; Fagan, KA; Gairhe, S; Gerthoffer, WT; Ito, M; Koubsky, K; McMurtry, IF; Oka, M; Ota, H; Toba, M | 1 |
| Akladios, CY; Aprahamian, M; Balboni, G; Bour, G; Marescaux, J; Mutter, D | 1 |
| Baker, SD; Calabrese, C; Campana, D; Fan, Y; Hu, S; Inaba, H; Niu, H; Orwick, S; Panetta, JC; Pounds, S; Rehg, JE; Rose, C; Rubnitz, JE; Yang, S | 1 |
| El-Deiry, WS; Ferrara, TA; Katz, SI; Mayes, PA; Smith, CD; Wang, W; Zhou, L | 1 |
| Cunningham, D; Okines, AF; Reynolds, AR | 1 |
| Caldwell, GA; Caldwell, KA; Dawson, TM; Dawson, VL; Hamamichi, S; Lee, BD; Liu, Z; Ray, A; Smith, WW; Yang, D | 1 |
| Chang, C; Hsu, CL; Huang, CK; Hung, YC; Jeng, LB; Lin, TY; Ma, WL; Wu, MH; Yeh, CC; Yeh, S | 1 |
| Choi, JS; Chung, SH; Joo, CK; Seo, JW | 1 |
| Abell, AN; Chen, X; Darr, DB; Duncan, JS; Earp, HS; Frye, SV; Gomez, SM; Granger, DA; Graves, LM; He, X; Hoadley, KA; Jin, J; Johnson, GL; Johnson, NL; Jordan, NV; Kim, WY; Kuan, PF; Major, B; Midland, AA; Nakamura, K; Perou, CM; Sharpless, NE; Smalley, DM; Usary, J; Whittle, MC; Zawistowski, JS; Zhou, B | 1 |
| Fujisawa, M; Gleave, ME; Kususda, Y; Miyake, H | 1 |
| Chung, AS; Ferrara, N; Finkle, D; Komuves, L; Kowanetz, M; Ngu, H; Peale, F; Wu, X; Zhuang, G | 1 |
| Cagan, RL; Dar, AC; Das, TK; Shokat, KM | 1 |
| Hatano, E; Iwaisako, K; Koyama, Y; Miyagawa-Hayashino, A; Nagata, H; Nakamura, K; Narita, M; Taura, K; Uemoto, S | 1 |
| Chan, CC; Huang, YT; Lee, KC; Lee, TY; Lin, HC; Yang, YY; Yeh, YC | 1 |
| Açmaz, G; Akkar, OB; Atilgan, R; Boztosun, A; Kosar, MI; Ozer, H | 1 |
| Fan, X; Haney, CR; Karczmar, GS; Markiewicz, E; Mustafi, D; Stadler, WM | 1 |
| Kong, LQ; Li, Q; Song, TQ; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, QB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Björkholm, M; Celsing, F; De Raeve, H; Fristedt, C; Grandér, D; Gruber, A; Jernberg-Wiklund, H; Johnsson, P; Kharaziha, P; Kokaraki, G; Laane, E; Li, Q; Osterborg, A; Panaretakis, T; Panzar, M; Vanderkerken, K; Zhivotovsky, B | 1 |
| Chang, CC; Chuang, CL; Hsieh, HG; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Teng, TH; Wang, SS | 1 |
| Allemeersch, J; Carmeliet, P; Casteleyn, C; Colle, I; Coulon, S; Geerts, A; Heindryckx, F; Libbrecht, L; Stassen, JM; Terrie, E; Van Vlierberghe, H | 1 |
| Chang, CC; Chen, YC; Hsin, IF; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Lin, YL | 1 |
| Altun, A; Boztosun, A; Gulturk, S; Kiliçkap, S; Müderris, II; Ozer, H; Yanik, A | 1 |
| Ceder, S; Kharaziha, P; Panaretakis, T; Sanchez, C | 1 |
| Benitez, A; Bowen, T; Lokeshwar, VB; Shamaldevi, N; Yates, TJ | 1 |
| Campo, E; Colomer, D; López-Guerra, M; Montraveta, A; Navarro, A; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Xargay-Torrent, S | 1 |
| Rapp, UR; Schreck, R | 1 |
| Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI | 1 |
| Desai, AA; Garcia, JG; Gomberg-Maitland, M; Husain, AN; Lang, RM; Liu, Y; Lussier, YA; Maitland, ML; Moreno-Vinasco, L; Ratain, MJ; Sam, L; Sammani, S; Singleton, PA | 1 |
7 review(s) available for sorafenib and Disease Models, Animal
| Article | Year |
|---|---|
Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.
Topics: Animals; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Disease Models, Animal; Humans; Immunotherapy; Liver Neoplasms; Mice; Nivolumab; Protein Kinase Inhibitors; Sorafenib | 2020 |
Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Aspirin; Biological Products; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Enzyme Activators; Female; Humans; Metformin; Phosphorylation; Signal Transduction; Sorafenib; Treatment Outcome | 2020 |
Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Neoplasms; Niacinamide; Phenylurea Compounds; Research Design; Sorafenib | 2016 |
Raf inhibitors as therapeutic agents against neurodegenerative diseases.
Topics: Animals; Benzenesulfonates; Brain; Disease Models, Animal; Drug Design; Encephalitis; Humans; Inflammation Mediators; Neurodegenerative Diseases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib | 2010 |
Developing better treatments in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Research Design; Sorafenib; Treatment Outcome | 2010 |
Targeting angiogenesis in esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Disease Models, Animal; Disease-Free Survival; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Raf kinases: oncogenesis and drug discovery.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Disease Models, Animal; Enzyme Inhibitors; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Signal Transduction; Sorafenib | 2006 |
164 other study(ies) available for sorafenib and Disease Models, Animal
| Article | Year |
|---|---|
Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Mice; Molecular Structure; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Sorafenib; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2011 |
Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Imidazoles; MCF-7 Cells; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Structure-Activity Relationship | 2015 |
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
Topics: Amines; Aniline Compounds; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Urea | 2016 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis.
Topics: Animals; Collagen; Disease Models, Animal; Drug Carriers; Fibrosis; Kidney; Kidney Diseases; Ligands; Mice; Mice, Inbred C57BL; Myofibroblasts; Nanoparticles; Sorafenib; Ureteral Obstruction | 2022 |
Anti-inflammatory effect of mesenchymal stem cells on hepatocellular carcinoma in the xenograft mice model.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Disease Models, Animal; Heterografts; Humans; Interleukin-10; Liver Neoplasms; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Nude; Rodent Diseases; Sorafenib; Tumor Necrosis Factor-alpha | 2022 |
Bone marrow-targetable Green Tea Catechin-Based Micellar Nanocomplex for synergistic therapy of Acute myeloid leukemia.
Topics: Animals; Bone Marrow; Catechin; Disease Models, Animal; Humans; Leukemia, Myeloid, Acute; Mice; Micelles; Sorafenib; Tea; Tissue Distribution | 2022 |
Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer.
Topics: Activating Transcription Factor 2; Animals; Cell Line, Tumor; Disease Models, Animal; Ferroptosis; Humans; Phenotype; Sorafenib; Stomach Neoplasms | 2023 |
Synergistic effects of concurrent photodynamic therapy with indocyanine green and chemotherapy in hepatocellular carcinoma cell lines and mouse models.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Humans; Indocyanine Green; Liver Neoplasms; Mice; Photochemotherapy; Photosensitizing Agents; Sorafenib | 2023 |
Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Endoplasmic Reticulum; Humans; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2023 |
Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer.
Topics: Animals; Apoptosis; Copper; Disease Models, Animal; Ferroptosis; Humans; Ionophores; Liver Neoplasms; Mice; Sorafenib | 2023 |
Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Humans; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2023 |
Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Artesunate; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Liver Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Sorafenib; TOR Serine-Threonine Kinases | 2019 |
Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Everolimus; Humans; Mice; Osteosarcoma; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Immunohistochemistry; Liver Neoplasms; Liver X Receptors; Male; Mice; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3B; Drug Resistance, Neoplasm; Female; Hep G2 Cells; Heterografts; Humans; Interleukin-6; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Octamer Transcription Factor-3; Prognosis; Sorafenib; STAT3 Transcription Factor | 2019 |
Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Middle Aged; Sorafenib; Survival Analysis; Tumor Microenvironment; Young Adult | 2020 |
Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Hedgehog Proteins; Humans; Liver Neoplasms; Mice; Organoids; Signal Transduction; Sorafenib | 2020 |
Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Phosphoproteins; Proteomics; Receptor, EphA2; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide.
Topics: Aged; Aged, 80 and over; Animals; Disease Models, Animal; Endothelial Cells; Female; Foot; HaCaT Cells; Hand; Heparin-binding EGF-like Growth Factor; Humans; Keratinocytes; Keratosis; Male; Mice, Inbred ICR; Middle Aged; Mitogen-Activated Protein Kinase 9; Models, Biological; Niacinamide; Phosphorylation; Protein Stability; Sirtuin 1; Skin; Sorafenib | 2020 |
Establishment and Preclinical Therapy of Patient-derived Hepatocellular Carcinoma Xenograft Model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Heterografts; Humans; Immunotherapy; Killer Cells, Natural; Liver Neoplasms; Mice; Mice, SCID; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Cornea; Corneal Neovascularization; Disease Models, Animal; Male; Protein Kinase Inhibitors; Rats, Wistar; Sorafenib; Vascular Endothelial Growth Factor A | 2020 |
Curcumin-enhanced antitumor effects of sorafenib via regulating the metabolism and tumor microenvironment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Curcumin; Disease Models, Animal; Drug Synergism; Functional Food; Liver Neoplasms; Mice; Mice, Inbred Strains; Sorafenib; Tumor Microenvironment | 2020 |
Effects of Combined Admistration of Imatinib and Sorafenib in a Murine Model of Liver Fibrosis.
Topics: Angiogenesis Inhibitors; Animals; Computer Simulation; Concanavalin A; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Hepatic Stellate Cells; Humans; Imatinib Mesylate; Liver; Liver Cirrhosis; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Sorafenib | 2020 |
CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; Cytoprotection; Disease Models, Animal; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; Mice; Sorafenib; Transfection; Urea | 2020 |
Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Precision Medicine; Prognosis; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thioacetamide; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Therapeutic response monitoring after targeted therapy in an orthotopic rat model of hepatocellular carcinoma using contrast-enhanced ultrasound: Focusing on inter-scanner, and inter-operator reproducibility.
Topics: Animals; Carcinoma, Hepatocellular; Contrast Media; Disease Models, Animal; Liver Neoplasms; Male; Perfusion; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sorafenib; Ultrasonography | 2020 |
Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cellular Microenvironment; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Inflammation Mediators; Liver Cirrhosis; Liver Neoplasms; Mice; Protein Kinase Inhibitors; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2021 |
HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness.
Topics: Acetylation; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Energy Metabolism; Gene Expression Profiling; Gene Silencing; Glycolysis; Hep G2 Cells; Histone Deacetylases; Histones; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Prognosis; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Signal Transduction; Sorafenib; Spheroids, Cellular; Tumor Stem Cell Assay | 2021 |
Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye.
Topics: Administration, Ophthalmic; Animals; Choroidal Neovascularization; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Emulsions; Female; Male; Mice; Mice, Inbred C57BL; Nanostructures; Protein Kinase Inhibitors; Rabbits; Rats; Rats, Sprague-Dawley; Retinal Diseases; Retinal Neovascularization; Sorafenib | 2021 |
Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Blood Platelets; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Mice; Signal Transduction; Sorafenib; Sulfonamides | 2021 |
Sorafenib Modulates the LPS- and Aβ-Induced Neuroinflammatory Response in Cells, Wild-Type Mice, and 5xFAD Mice.
Topics: Alzheimer Disease; Animals; Astrocytes; Cyclooxygenase 2; Disease Models, Animal; Inflammation; Interleukin-1beta; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Microglia; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib | 2021 |
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Administration, Topical; Anemia; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Disease Models, Animal; Erlotinib Hydrochloride; Gastrointestinal Hemorrhage; Hemoglobins; Image Processing, Computer-Assisted; Indazoles; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Skin; Sorafenib; Sulfonamides; Sulfones; Telangiectasia, Hereditary Hemorrhagic; Tyrosine; Vascular Endothelial Growth Factor A; Wound Healing | 2017 |
Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Chemoembolization, Therapeutic; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Drug Liberation; Liver Neoplasms; Magnetic Resonance Imaging; Male; Materials Testing; Microspheres; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; Tissue Distribution; Tomography, X-Ray Computed; Treatment Outcome; Triiodobenzoic Acids; Xenograft Model Antitumor Assays | 2017 |
Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Liver Neoplasms; Mice; Niacinamide; NIMA-Interacting Peptidylprolyl Isomerase; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Disease Models, Animal; DNA; Doxorubicin; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Osteosarcoma; Phenylurea Compounds; RNA; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cohort Studies; Disease Models, Animal; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Mice, Inbred BALB C; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Disulfide-Isomerases; Random Allocation; RNA, Messenger; Sorafenib; Statistics, Nonparametric; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis.
Topics: Animals; Apoptosis; Bile Ducts; Carbon Tetrachloride; Cell Line; Cell Proliferation; Disease Models, Animal; Hepatic Stellate Cells; Humans; Ligation; Liver Cirrhosis; Male; Mice, Inbred C57BL; Mutation; Phenyl Ethers; Phenylurea Compounds; Protein Domains; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Rats; Sorafenib; STAT3 Transcription Factor | 2017 |
Anti-tumor Effects of Sorafenib Administered at Different Time Points in Combination with Transarterial Embolization in a Rabbit VX2 Liver Tumor Model.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Disease Models, Animal; Drug Administration Schedule; Embolization, Therapeutic; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib | 2017 |
Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.
Topics: Animals; Apoptosis; Cell Death; Disease Models, Animal; Humans; Inflammation; Mice; Necrosis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinases; Receptor-Interacting Protein Serine-Threonine Kinases; Reperfusion Injury; Sorafenib; Tumor Necrosis Factor-alpha | 2017 |
Global Metabolic Profiling Identifies a Pivotal Role of Proline and Hydroxyproline Metabolism in Supporting Hypoxic Response in Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Energy Metabolism; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Metabolome; Metabolomics; Phenotype; Proline; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
The effect of selected molecules influencing the detrimental host immune response on a course of rabies virus infection in a murine model.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cricetinae; Disease Models, Animal; Female; Immunity, Innate; Interleukin-6; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Rabies; Rabies virus; Sorafenib; Tumor Necrosis Factor-alpha | 2019 |
The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Topics: AC133 Antigen; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3B; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Liver Neoplasms; Mice; MicroRNAs; Phenotype; PTEN Phosphohydrolase; Rats; Sorafenib; TOR Serine-Threonine Kinases | 2018 |
A whole-animal platform to advance a clinical kinase inhibitor into new disease space.
Topics: Animals; Animals, Genetically Modified; Carcinoma; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Drosophila; Drug Design; Female; HCT116 Cells; Humans; Male; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Neoplasm Transplantation; Protein Isoforms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2018 |
Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway.
Topics: Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Monounsaturated; Fluvastatin; Hepatic Stellate Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kupffer Cells; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Real-Time Polymerase Chain Reaction; Smad3 Protein; Sorafenib; Transforming Growth Factor beta1 | 2018 |
Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bufanolides; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Humans; Male; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Cluster versus ROI analysis to assess combined antiangiogenic therapy and radiotherapy in the F98 rat-glioma model.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Cluster Analysis; Disease Models, Animal; Glioma; Magnetic Resonance Imaging; Male; Rats, Inbred F344; Sorafenib | 2018 |
Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Autophagy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Indoles; Male; Monocrotaline; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pulmonary Artery; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling | 2018 |
Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Male; Mice; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Sorafenib; Vorinostat | 2019 |
Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Docosahexaenoic Acids; Drug Synergism; Fish Oils; Genes, Reporter; Heme Oxygenase-1; Humans; Mice; Mice, Nude; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
Topics: Animals; Biomarkers, Tumor; Capillary Permeability; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Hypoxia; Image Processing, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Imaging; Male; Necrosis; Neovascularization, Pathologic; Permeability; Rats; Sorafenib | 2019 |
TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Liver Neoplasms; Mice; Models, Biological; Protein Kinase Inhibitors; Sorafenib; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2019 |
CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Topics: Animals; Antibodies, Bispecific; Antibody Affinity; Antibody Specificity; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Immunological; CD24 Antigen; Cell Degranulation; Cell Line, Tumor; Cytokines; Disease Models, Animal; Drug Synergism; Genetic Vectors; Histocompatibility Antigens Class I; Humans; Immunoglobulin Fc Fragments; Immunotherapy; Killer Cells, Natural; Leukocytes, Mononuclear; Mice; Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Receptors, Fc; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Heterografts; Humans; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Carcinoma, Anaplastic | 2019 |
Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.
Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Disease Models, Animal; DNA Methylation; Down-Regulation; Drug Resistance; Genetic Therapy; Humans; Immunoblotting; Male; Octamer Transcription Factor-1; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Statistics, Nonparametric | 2019 |
Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.
Topics: Analysis of Variance; Animals; Carcinoma, Hepatocellular; Cytokines; Disease Models, Animal; Female; Flow Cytometry; Humans; Injections, Intravenous; Killer Cells, Natural; Liver Neoplasms; Macrophages; Mice; Mice, Transgenic; Protein Kinase Inhibitors; Pyroptosis; Random Allocation; Sorafenib; Tumor Burden; Tumor Cells, Cultured; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2019 |
Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Cytokines; Disease Models, Animal; Drug Resistance, Neoplasm; Glypicans; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Macrophages; Mice; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Sorafenib; T-Lymphocytes; Xenograft Model Antitumor Assays | 2019 |
Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Imaging; Molecular Targeted Therapy; Multimorbidity; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2019 |
Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Humans; Mice; Neoplasm Recurrence, Local; Osteosarcoma; Piperazines; Pyridines; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase.
Topics: Animals; Apoptosis; Disease Models, Animal; Disease-Free Survival; Extracellular Signal-Regulated MAP Kinases; Liver Neoplasms, Experimental; Liver Transplantation; Male; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Rats, Inbred ACI; Rats, Inbred Lew; Sorafenib; Tissue Array Analysis | 2013 |
Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Immunocompromised Host; Immunosuppressive Agents; K562 Cells; Killer Cells, Natural; Lectins, C-Type; Liver Neoplasms; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy.
Topics: alpha-Fetoproteins; Animals; Autophagy-Related Protein 5; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Gene Order; Gene Silencing; Genetic Vectors; Homologous Recombination; Humans; Liver Neoplasms; Male; Mice; Microtubule-Associated Proteins; Niacinamide; Organ Specificity; Phenylurea Compounds; Promoter Regions, Genetic; RNA Interference; Sorafenib; Tumor Burden | 2013 |
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Line, Tumor; Disease Models, Animal; Humans; Hypoxia; Imidazoles; Indazoles; Male; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.
Topics: Acetyltransferases; Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Diethylnitrosamine; Disease Models, Animal; Granulocyte-Macrophage Colony-Stimulating Factor; Heterografts; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-myc; Sorafenib | 2013 |
Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Diphenylamine; Disease Models, Animal; Dogs; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Early prediction of treatment response to sorafenib with elastosonography in a mice xenograft model of hepatocellular carcinoma: a proof-of-concept study.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Elasticity Imaging Techniques; Female; Heterografts; Liver; Liver Neoplasms, Experimental; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tumor Burden | 2013 |
A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 8; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Gene Expression; Humans; Interferon-gamma; Liver Neoplasms; Male; NF-kappa B; Niacinamide; Phenylurea Compounds; Rats; RNA, Double-Stranded; Sorafenib; Toll-Like Receptor 3; Transcriptional Activation; Tumor Burden | 2013 |
The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.
Topics: Animals; Common Bile Duct; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Hepatopulmonary Syndrome; Ligation; Lung; Male; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
Combination of targeted PDT and anti-VEGF therapy for rat CNV by RGD-modified liposomal photocyanine and sorafenib.
Topics: Animals; Choroidal Neovascularization; Disease Models, Animal; Fluorescein Angiography; Fundus Oculi; Humans; Liposomes; Male; Niacinamide; Oligopeptides; Phenylurea Compounds; Photochemotherapy; Photosensitizing Agents; Rats; Rats, Inbred BN; Receptors, Immunologic; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
Topics: Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; CD11b Antigen; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Disease Models, Animal; Hepatocyte Growth Factor; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Mice, Knockout; Myeloid Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Receptors, Chemokine; Receptors, CXCR4; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sorafenib | 2014 |
Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Clusterin; Disease Models, Animal; Drug Resistance, Neoplasm; Inhibitory Concentration 50; Kidney Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Transcriptome | 2014 |
Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
Topics: Animals; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; Female; Imiquimod; Kidney Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Disease Models, Animal; Drug Repositioning; Indoles; Inhibitory Concentration 50; Lapatinib; Leishmania; Leishmaniasis; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Indoles; Kidney Neoplasms; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Pyrroles; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Synergism; Female; Humans; Immunophenotyping; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mice; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); raf Kinases; Signal Transduction; Sorafenib; Sulfonamides; Survivin; Wnt Signaling Pathway | 2014 |
Sorafenib cardiotoxicity increases mortality after myocardial infarction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cats; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Heart; In Vitro Techniques; Male; Metoprolol; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib | 2014 |
Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Heterografts; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway.
Topics: Animals; Becaplermin; Blood Pressure; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Heart Ventricles; Hypertrophy, Left Ventricular; Male; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins c-sis; Rats; Rats, Inbred Lew; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Sorafenib; Transforming Growth Factor beta1 | 2014 |
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
An inducible hepatocellular carcinoma model for preclinical evaluation of antiangiogenic therapy in adult mice.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Humans; Liver Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Transgenic; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Cell Proliferation; Disease Models, Animal; Down-Regulation; Female; Heterografts; Humans; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Random Allocation; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Salivary Gland Neoplasms; Sensitivity and Specificity; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2015 |
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Regulatory Factor X Transcription Factors; Regulatory Factor X1; Sorafenib; STAT3 Transcription Factor; Transcription Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2014 |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Humans; Immunologic Factors; Interferon-gamma; Lenalidomide; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocyte Subsets; Thalidomide | 2014 |
FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.
Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Burden | 2014 |
Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Administration Schedule; Immunosuppressive Agents; Immunotherapy, Adoptive; Lymphoma; Mice; Mice, Transgenic; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Microenvironment | 2014 |
Possible Role of Raf-1 Kinase in the Development of Cerebral Vasospasm and Early Brain Injury After Experimental Subarachnoid Hemorrhage in Rats.
Topics: Animals; Basilar Artery; Blood-Brain Barrier; Brain Damage, Chronic; Brain Edema; Cyclooxygenase 2; Disease Models, Animal; Down-Regulation; Interleukin-1beta; Interleukin-6; Male; MAP Kinase Kinase Kinases; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinase Kinases; Nerve Tissue Proteins; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-raf; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Sorafenib; Subarachnoid Hemorrhage; Vascular Endothelial Growth Factor A; Vasospasm, Intracranial | 2015 |
Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Disease Models, Animal; Humans; Immunotherapy; Killer Cells, Natural; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |
Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Immunohistochemistry; Liver; Liver Neoplasms; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Electron; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Tumor Burden | 2015 |
Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Injections, Intra-Arterial; Iodized Oil; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Treatment Outcome | 2014 |
Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.
Topics: Actins; Animals; Apoptosis; Cadherins; Cell Line; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Immunohistochemistry; Kidney Diseases; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Smad3 Protein; Sorafenib; Transforming Growth Factor beta; Ureteral Obstruction | 2015 |
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.
Topics: Animals; Chaperonin 60; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Fibrillar Collagens; Glutathione Transferase; HSP90 Heat-Shock Proteins; Interleukin-10; Interleukin-6; Liver Cirrhosis; Matrix Metalloproteinase 9; Mitochondria, Liver; Niacinamide; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phenylurea Compounds; Polarography; Protein Kinase Inhibitors; Rats, Sprague-Dawley; RNA, Messenger; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transcription Factors | 2015 |
Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD47 Antigen; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, SCID; Molecular Targeted Therapy; NF-kappa B; Niacinamide; Phenylurea Compounds; Random Allocation; Signal Transduction; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Disease Models, Animal; Everolimus; Genetic Engineering; Homozygote; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Knockout; Neoplasms, Experimental; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; PTEN Phosphohydrolase; Signal Transduction; Sorafenib | 2015 |
Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Proliferation; Disease Models, Animal; Endometriosis; Endometrium; Female; Indazoles; Indoles; Niacinamide; Ovarian Reserve; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Comparative Genomic Hybridization; Disease Models, Animal; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Neoplasm Grading; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Sorafenib | 2015 |
Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Renal Cell; Contrast Media; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Feasibility Studies; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2015 |
Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
Topics: Adult; Animals; Apoptosis; Case-Control Studies; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endometriosis; Endometrium; Extracellular Signal-Regulated MAP Kinases; Female; Heterografts; Humans; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Stromal Cells; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Next Generation of Preclinical Liver Cancer Models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Comparative Genomic Hybridization; Disease Models, Animal; Genetic Heterogeneity; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Sorafenib | 2015 |
A model of neuropathic pain induced by sorafenib in the rat: Effect of dimiracetam.
Topics: Analgesics; Analysis of Variance; Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Imidazoles; Male; Neuralgia; Niacinamide; Pain Measurement; Pain Threshold; Phenylurea Compounds; Pyrroles; Rats; Rats, Sprague-Dawley; Reaction Time; Sorafenib; Time Factors | 2015 |
Feasibility of Using Volumetric Contrast-Enhanced Ultrasound with a 3-D Transducer to Evaluate Therapeutic Response after Targeted Therapy in Rabbit Hepatic VX2 Carcinoma.
Topics: Animals; Antineoplastic Agents; Contrast Media; Disease Models, Animal; Feasibility Studies; Image Enhancement; Imaging, Three-Dimensional; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rabbits; Reproducibility of Results; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2015 |
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; Receptors, Interleukin-8B; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
In vitro and in vivo activity of a novel sorafenib derivative SC5005 against MRSA.
Topics: Animals; Anti-Bacterial Agents; Caenorhabditis elegans; Cell Line; Cell Survival; Disease Models, Animal; Female; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred C57BL; Microbial Sensitivity Tests; Niacinamide; Phenylurea Compounds; Sorafenib; Staphylococcal Infections; Staphylococcus epidermidis; Survival Analysis; Treatment Outcome | 2016 |
Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aporphines; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Protein-beta; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Female; G2 Phase Cell Cycle Checkpoints; Humans; Liver Neoplasms; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
Topics: Animals; Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Female; Flavonoids; Flavonols; HeLa Cells; Humans; Membrane Potential, Mitochondrial; Mitochondria; Niacinamide; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Sorafenib; Tumor Burden; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Carcinoma, Hepatocellular; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Hepatectomy; Hepatitis; Immunoenzyme Techniques; Inflammation; Liver Neoplasms; Liver Regeneration; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Array Analysis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib | 2016 |
Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model.
Topics: Animals; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Immunotherapy; Macrophages; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Phototherapy; RAW 264.7 Cells; Sorafenib | 2016 |
Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cytotoxicity, Immunologic; Disease Models, Animal; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy, Adoptive; Interleukin-12 Subunit p35; Killer Cells, Natural; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Receptors, Androgen; Signal Transduction; Sorafenib; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Actins; Animals; Antigens, CD34; Antineoplastic Agents; Blood Vessels; Carcinoma, Hepatocellular; Contrast Media; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Homeodomain Proteins; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, SCID; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Osteopontin; Phenylurea Compounds; Repressor Proteins; Sequence Analysis, RNA; Signal Transduction; Sorafenib; Ultrasonography; Up-Regulation; Vascular Endothelial Growth Factor A; Vimentin; Zinc Finger E-box Binding Homeobox 2; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities.
Topics: Animals; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Echocardiography; Electrocardiography; Heart Defects, Congenital; Heart Rate; Hemodynamics; Male; Mice; Myocardial Contraction; Niacinamide; Organ Size; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Tadalafil; Thyroxine | 2016 |
Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; beta Catenin; Cell Proliferation; Cyclin D1; Disease Models, Animal; Glutathione; Histocytochemistry; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rats; Sorafenib; Treatment Outcome | 2017 |
Iron depletion enhances the effect of sorafenib in hepatocarcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Humans; Iron; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis | 2016 |
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Cytotoxicity, Immunologic; Disease Models, Animal; Humans; Immunophenotyping; Immunotherapy; Immunotherapy, Adoptive; Killer Cells, Natural; Liver Neoplasms; Lymphocyte Activation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Endometrial Neoplasms; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyridines; Sorafenib; Thyroid Neoplasms | 2016 |
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Genes, myc; Humans; Liver Neoplasms; Mice; Niacinamide; Nuclear Proteins; Oligopeptides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; raf Kinases; ras Proteins; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Transcription Initiation Site; Xenograft Model Antitumor Assays | 2016 |
The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Receptors, Androgen; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Genetic Vectors; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Interference; RNA, Long Noncoding; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Cell Adhesion; Cell Movement; Chemokine CCL2; Chemokine CXCL11; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Humans; Kidney Tubules; Macrophages; Male; Mice; Mice, Inbred C57BL; Myofibroblasts; Niacinamide; Phenylurea Compounds; Receptors, CXCR3; RNA, Messenger; Signal Transduction; Sorafenib; Transforming Growth Factor beta1; Ureter; Ureteral Obstruction | 2016 |
Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Mice; Necrosis; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
Topics: Animals; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cell Survival; Depsipeptides; Disease Models, Animal; Humans; Meningeal Neoplasms; Meningioma; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2017 |
Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2
Topics: Animals; ATP-Binding Cassette Transporters; Cell Death; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Everolimus; GTPase-Activating Proteins; Kidney Neoplasms; Mice; Mice, Knockout; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Tuberous Sclerosis | 2017 |
Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Disease Models, Animal; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation; Histones; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models.
Topics: Animals; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Heterografts; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Body Weight; Disease Models, Animal; Disease Progression; Exons; Gastrointestinal Stromal Tumors; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Female; Flow Cytometry; Immunohistochemistry; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib | 2009 |
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunohistochemistry; Lentivirus Infections; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Signal Transduction; Smad2 Protein; Sorafenib; Stomach Neoplasms; Thrombospondin 1; Transforming Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2009 |
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Topics: Animals; Atorvastatin; Benzenesulfonates; Cystadenoma; Disease Models, Animal; Doxycycline; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Heptanoic Acids; Immunosuppressive Agents; Interferon-gamma; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Burden; Tumor Suppressor Proteins | 2009 |
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Disease Models, Animal; Humans; Indoles; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Blotting, Western; Disease Models, Animal; Drug Synergism; Humans; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms | 2009 |
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Okadaic Acid; Phenylurea Compounds; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Highlights from the Eigth International Kidney Cancer Symposium.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Humans; Kidney Neoplasms; Multigene Family; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2009 |
Sorafenib exerts anti-glioma activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glioblastoma; Glioma; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Random Allocation; Sorafenib; Treatment Outcome | 2010 |
Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media.
Topics: Analysis of Variance; Animals; Area Under Curve; Benzenesulfonates; Blood-Brain Barrier; Brain Neoplasms; Contrast Media; Disease Models, Animal; Glioma; Heterocyclic Compounds; Macromolecular Substances; Magnetic Resonance Imaging; Male; Neovascularization, Pathologic; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Pyridines; Random Allocation; Rats; Sorafenib | 2010 |
Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transplantation, Heterologous; Treatment Outcome | 2011 |
Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Cytarabine; Disease Models, Animal; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloid-Lymphoid Leukemia Protein; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Survival Analysis; Tandem Repeat Sequences; Tumor Suppressor Protein p53 | 2011 |
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Proliferation; Chromatography, High Pressure Liquid; Disease Models, Animal; Drug Evaluation, Preclinical; Everolimus; Female; Hedgehog Proteins; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Integrases; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurofibroma, Plexiform; Neurofibromin 1; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sirolimus; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution; Tumor Burden | 2012 |
Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.
Topics: Animals; Antihypertensive Agents; Benzamides; Benzenesulfonates; Blotting, Western; Calcium; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Pulmonary; Imatinib Mesylate; Male; Myosin Light Chains; Myosin-Light-Chain Phosphatase; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pulmonary Artery; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Sorafenib; Vasodilation; Vasodilator Agents; Ventricular Function, Left; Ventricular Function, Right; Ventricular Pressure | 2011 |
[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Deoxycytidine; Disease Models, Animal; Disease Progression; Doxorubicin; Drug Monitoring; Gemcitabine; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Rats; Rats, Inbred ACI; Sorafenib; Survival Analysis; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2011 |
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP-Binding Cassette Transporters; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatography, High Pressure Liquid; Confounding Factors, Epidemiologic; Cytarabine; Disease Models, Animal; Drug Administration Schedule; Gene Expression Regulation, Neoplastic; Humans; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Tandem Mass Spectrometry; Time Factors; Transplantation, Heterologous; Treatment Outcome | 2011 |
FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Recombinant Proteins; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
Topics: Animals; Animals, Genetically Modified; Benzenesulfonates; Caenorhabditis elegans; Cell Survival; Disease Models, Animal; Dopaminergic Neurons; Drosophila; Enzyme Activation; Humans; Indoles; Motor Activity; Mutation; Niacinamide; Oxidopamine; Parkinson Disease; Phenols; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Sorafenib; Synucleins | 2011 |
Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.
Topics: Animals; Anoikis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Knockout; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Random Allocation; Receptors, Androgen; Sorafenib; Tumor Cells, Cultured | 2012 |
Inhibition of corneal neovascularization in rats by systemic administration of sorafenib.
Topics: Administration, Oral; Animals; Benzenesulfonates; Blotting, Western; Corneal Neovascularization; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Breast Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Kinase 1; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proteome; Proto-Oncogene Proteins c-myc; Pyridines; Receptor Protein-Tyrosine Kinases; Sorafenib | 2012 |
Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Clusterin; Disease Models, Animal; Gene Knockdown Techniques; Humans; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Oligonucleotides, Antisense; Phenylurea Compounds; Pyridines; Sorafenib; Thionucleotides; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Imatinib Mesylate; In Vitro Techniques; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
Topics: Animals; Benzenesulfonates; Cell Transformation, Neoplastic; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Extracellular Signal-Regulated MAP Kinases; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Molecular Targeted Therapy; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Polypharmacy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; src-Family Kinases; Survival Rate; Xenograft Model Antitumor Assays | 2012 |
Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9.
Topics: Animals; Disease Models, Animal; Down-Regulation; Hepatectomy; Hepatic Veno-Occlusive Disease; Liver; Male; MAP Kinase Kinase 4; Matrix Metalloproteinase 9; Monocrotaline; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib | 2012 |
Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
Topics: Animals; Apoptosis; Disease Models, Animal; Fatty Liver; Gene Expression Regulation, Enzymologic; Hemodynamics; Inflammation; Liver; Male; MAP Kinase Signaling System; Necrosis; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion Injury; rho-Associated Kinases; RNA, Messenger; Sorafenib; Transplantation, Homologous | 2012 |
The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Disease Models, Animal; Endometriosis; Female; Microvessels; Niacinamide; Phenylurea Compounds; Random Allocation; Rats; Rats, Wistar; Sorafenib; Treatment Outcome; Tretinoin | 2013 |
Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
Topics: Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Contrast Media; Disease Models, Animal; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Transplantation, Heterologous | 2013 |
Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Hep G2 Cells; Humans; Janus Kinases; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Repressor Proteins; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transplantation, Heterologous; Tumor Suppressor Proteins | 2012 |
Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Disease Models, Animal; DNA Primers; Female; Flow Cytometry; Humans; Immunohistochemistry; Male; Mice; Middle Aged; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis.
Topics: Animals; Benzenesulfonates; Common Bile Duct; Disease Models, Animal; Hemodynamics; Hepatopulmonary Syndrome; Ligation; Liver; Liver Cirrhosis, Biliary; Liver Diseases; Lung; Male; Niacinamide; Oxygen; Partial Pressure; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamine; Disease Models, Animal; Drug Therapy, Combination; Liver Neoplasms; Mice; Mice, Knockout; Mice, Transgenic; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placenta Growth Factor; Pregnancy Proteins; Sorafenib; Treatment Outcome | 2013 |
The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats.
Topics: Animals; Disease Models, Animal; Hepatic Encephalopathy; Humans; Hypertension, Portal; Liver Cirrhosis, Experimental; Male; Niacinamide; Oxidative Stress; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib | 2012 |
The effect of sorafenib in postoperative adhesion formation in a rat uterine horn model.
Topics: Animals; Benzenesulfonates; Disease Models, Animal; Female; Immunohistochemistry; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Rats; Rats, Wistar; Sorafenib; Tissue Adhesions; Uterine Diseases; Uterus; Vascular Endothelial Growth Factor A | 2012 |
Multitargeted therapies for multiple myeloma.
Topics: Animals; Disease Models, Animal; Humans; Mice; Models, Biological; Molecular Targeted Therapy; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Sorafenib | 2013 |
Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Dietary Supplements; Disease Models, Animal; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Hymecromone; Immunoblotting; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Random Allocation; Sensitivity and Specificity; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclin D1; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins c-bcl-2; Receptors, Antigen, B-Cell; Signal Transduction; Sorafenib; Stromal Cells; Transplantation, Heterologous | 2013 |
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Movement; Cell Proliferation; Disease Models, Animal; Endothelial Cells; Eye Neoplasms; Humans; In Vitro Techniques; Lenalidomide; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Thalidomide; Xenograft Model Antitumor Assays | 2007 |
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Complement C1q; Disease Models, Animal; Enzyme Activation; Gene Expression Profiling; Genomics; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Mitogen-Activated Protein Kinases; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Inbred Dahl; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Transforming Growth Factor beta3; Vascular Endothelial Growth Factor Receptor-2 | 2008 |